Pages that link to "Q35562475"
Jump to navigation
Jump to search
The following pages link to Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children (Q35562475):
Displaying 50 items.
- Immunoglobulin treatment for respiratory syncytial virus infection (Q24235607) (← links)
- Immunoglobulin treatment for respiratory syncytial virus infection (Q24243780) (← links)
- The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature (Q28067526) (← links)
- Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role (Q30145641) (← links)
- Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity (Q30946151) (← links)
- Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention (Q33339086) (← links)
- Bronchiolitis (Q33446856) (← links)
- Nasal IgA response in wheezy infants (Q33623247) (← links)
- Genomewide association analysis of respiratory syncytial virus infection in mice (Q33648868) (← links)
- Intranasal antibody prophylaxis for protection against viral disease. (Q33683058) (← links)
- Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice (Q33782181) (← links)
- Active and passive immunisation against respiratory syncytial virus (Q33782438) (← links)
- Respiratory syncytial virus infection: clinical presentation and management (Q33929017) (← links)
- Community respiratory virus infections in immunocompromised patients with cancer (Q33950804) (← links)
- Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients (Q33950838) (← links)
- Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases (Q33999369) (← links)
- New insights for development of a safe and protective RSV vaccine (Q34249859) (← links)
- Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. (Q34307704) (← links)
- Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice (Q35046469) (← links)
- Topically administered immunoglobulin reduces pulmonary respiratory syncytial virus shedding in owl monkeys (Q35319145) (← links)
- The respiratory syncitial virus and its role in acute bronchiolitis (Q35376297) (← links)
- Respiratory syncytial virus infections (Q35480437) (← links)
- Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice (Q35823116) (← links)
- Human coronavirus NL63, a new respiratory virus (Q36566597) (← links)
- Respiratory syncytial virus: Virology, diagnosis, and vaccination (Q36591094) (← links)
- Human antibodies from combinatorial libraries. (Q36717602) (← links)
- Management of Reactive Airway Disease (Q36744267) (← links)
- Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection of cotton rats (Q36808652) (← links)
- Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virus (Q36933029) (← links)
- Antiviral therapy for respiratory tract infections (Q37298680) (← links)
- New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections (Q37831865) (← links)
- Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis (Q37841264) (← links)
- Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention (Q37841269) (← links)
- Respiratory syncytial virus: current and emerging treatment options (Q38210541) (← links)
- Nosocomial viral infections: recent developments and new strategies (Q38222773) (← links)
- Therapeutic uses of intravenous gammaglobulin for pediatric infections. (Q39602970) (← links)
- Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract (Q40158643) (← links)
- Inhibition of human coronavirus NL63 infection at early stages of the replication cycle (Q40275624) (← links)
- Clinical immunology and infectious diseases. (Q40391241) (← links)
- Bronchiolitis. Origins and optimal management. (Q40463604) (← links)
- Respiratory syncytial virus (Q40485832) (← links)
- Treatment of respiratory syncytial virus infections in children (Q40573404) (← links)
- Treatment and prevention options for respiratory syncytial virus infections (Q40746072) (← links)
- Respiratory syncytial virus (RSV) disease and prospects for its control (Q40836386) (← links)
- Respiratory syncytial virus infection in children with congenital heart disease: a review (Q41004650) (← links)
- Respiratory syncytial virus immune globulin intravenous (Q41316287) (← links)
- Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery (Q41676840) (← links)
- IgG and IgM antibodies to viral glycoproteins in respiratory syncytial virus infections of graded severity (Q42155005) (← links)
- Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus (Q42855455) (← links)
- Respiratory Syncytial Virus Immune Globulin Treatment of RSV Lower Respiratory Tract Infection in Previously Healthy Children (Q43927324) (← links)